• InstaBlue Protein Stain Solution for Neurobiology

  2026-08-19

  InstaBlue Protein Stain Solution enables rapid, solvent-free protein gel visualization for neuronal hypoxia and ferroptosis workflows. Its short staining time, low detection threshold, and mass spectrometry compatibility help researchers move efficiently from electrophoresis quality control to mechanistic protein analysis.

• SAR405: Precision Control of Vps34 and Autophagy

  2026-08-19

  SAR405 is a selective Vps34 inhibitor for separating autophagy initiation from downstream PtdIns3P production and membrane trafficking. Its value is greatest in nutrient-stress matrices, GFP-FYVE or GFP-LC3 assays, lysosomal phenotyping, and combination studies with mTOR inhibitors.

• Cefepime in CNS Infection Research

  2026-08-18

  Cefepime (BMY-28142) offers translational researchers a mechanistically grounded platform for connecting β-lactam activity, blood–brain barrier exposure, resistance dynamics, and neurotoxicity readouts in central nervous system infection models.

• STING agonist-1: B-Cell Assay Workflows

  2026-08-18

  Use STING agonist-1 as a controlled perturbation for dissecting innate immune signaling, IRF4-associated B-cell activation, and tumor-immunity phenotypes. This workflow emphasizes dose finding, orthogonal readouts, pathway controls, and practical handling of a DMSO-soluble research reagent.

• Diethylmaleate for GSH Depletion Workflows

  2026-08-17

  Diethylmaleate provides a practical way to perturb glutathione-dependent defenses and connect redox changes with GST activity, ROS, apoptosis, and chemical resistance. This workflow-oriented guide translates insecticide-resistance evidence into controlled assay designs while separating validated findings from optimization recommendations.

• GDC-0994 ERK1/2 Inhibitor Workflows

  2026-08-17

  GDC-0994 provides a selective way to connect ERK1/2 signaling with measurable outcomes in BRAF- or RAS-driven cancer models and estrogen-associated cholestasis studies. This guide translates the reference findings into practical dosing, pathway-validation, and troubleshooting workflows.

• A-769662: Practical AMPK Activation Workflows

  2026-08-16

  A-769662 provides a reversible way to interrogate AMPK-driven energy metabolism without relying solely on nutrient starvation. This workflow-centered guide connects fatty acid synthesis inhibition, autophagy interpretation, and proteasome-related cell-cycle effects while emphasizing controls that separate AMPK-dependent from off-target biology.

• Nonselective β-Blockers and Hematopoietic Recovery

  2026-08-15

  The reference study shows that nonselective β-adrenergic receptor inhibitors can delay hematopoietic regeneration after allogeneic transplantation, whereas β1-selective inhibition with Metoprolol Tartrate was not associated with the same impairment in the tested models. Its integrated mouse and clinical analyses identify transplant type, posttransplant chemotherapy, and graft-cell dose as important modifiers of this association.

• Anlotinib hydrochloride in Angiogenesis Assays

  2026-08-14

  Anlotinib hydrochloride gives researchers a practical way to connect VEGFR2, PDGFRβ, and FGFR1 signaling with measurable endothelial migration, tube formation, and ERK responses. This workflow-focused guide covers assay setup, comparative benchmarking, translational interpretation, and troubleshooting for cancer research.

• A-769662: AMPK Activator Workflows

  2026-08-14

  A-769662 provides reversible, allosteric AMPK activation for dissecting energy metabolism, fatty acid synthesis inhibition, and nutrient-stress signaling. Its activity can also expose AMPK-independent proteasome effects, making parallel pathway and viability controls essential in metabolic and autophagy experiments.

• CX-4945 (Silmitasertib) in CK2 Lung Cancer Models

  2026-08-13

  CX-4945 (Silmitasertib) provides a mechanistic framework for studying CK2-driven stability, stemness, chemoresistance, and invasion in lung cancer. This article translates recent ECE-1c findings into practical assay and interpretation strategies.

• Cisapride for iPSC-CM Cardiac Safety Screens

  2026-08-13

  Cisapride (R 51619) combines 5-HT4 receptor activation with potent hERG channel inhibition, making it a useful mechanistic benchmark for cardiac electrophysiology research. This guide translates that dual pharmacology into iPSC-cardiomyocyte, high-content imaging, and orthogonal electrophysiology workflows with practical troubleshooting.

• Sulfaphenazole Restores Diabetic Vascular Function

  2026-08-12

  The reference study showed that pharmacological CYP2C inhibition with Sulfaphenazole restored acetylcholine-dependent vasodilation in db/db diabetic mice without lowering plasma glucose. Its key contribution was to connect CYP-derived oxidative stress with reduced nitric oxide bioavailability and impaired endothelial function, offering a mechanistic framework for vascular endothelial function research.

• Tamoxifen as a Mechanistic Probe in MCF-7 Assays

  2026-08-12

  Tamoxifen, a selective estrogen receptor modulator, can serve as more than a treatment control. This article explains how to use its pharmacology to interpret caveolin-1, migration, cytotoxicity, and CreER-mediated gene knockout experiments with greater mechanistic precision.

• Cell Counting Kit-8 in Mutant p53 Cancer Models

  2026-08-11

  Use CCK8 to quantify genotype-dependent proliferation, drug sensitivity, and viability in mutant p53 cancer models. A controlled WST-8 workflow can complement replication-stress and cGAS–STING studies while clarifying where metabolic readouts require orthogonal validation.

16286 records 1/1086 page Next 12345 下5页 Last page